Wednesday, 22 November 2017

3rd session for CPIPR Sept to Dec 2017 Batch conducted

3rd module for the CPIPR September to December 2017 session has been uploaded on facebook and youtube. It can be accessed free of cost for everyone.

The lecture is delivered by Mayank Gupta, Manager, Sun Pharma.

Youtube:           https://www.youtube.com/watch?v=OydW6adEmWI


Thursday, 16 November 2017

NAAC Accreditation results_30th October 2017_Pharmacy Colleges

On 30th October, NAAC published the results for the accreditation by the 28th Standing Committee-30th October 2017. Following pharmacy institutions were accredited in the 1st Cycle. No pharmacy institute was accredited in the 2nd, 3rd or 4th cycle.

Name of the institution
State
CGPA
Grade
Annamacharya College of Pharmacy, New
Boyanapalli, Rajampet, Kadapa – 516216.
Andhra Pradesh
3.08
A
Seven Hills College of Pharmacy,
Venkatramapuram, Tanepally,
Ramachandrapuram, Tirupati, Chittoor –
517561
Andhra Pradesh
3.02
A
Indira Institute of Pharmacy, Sadavali,
Sangameshwar, Ratnagiri – 415804
Maharashtra
2.09
B
Kalyani Charitable Trusts Ravindra Gambhirrao Sapkal College of Pharmacy, Nashik – 422213
Maharashtra
2.52
B+
Shree Chanakya Education Society's Indira
College of Pharmacy, Tathawade, Pune –
411033
Maharashtra
2.78
B++
St. John Institute of Pharmacy and Research,
Palghar – 401404
Maharashtra
2.40
B
JDT Islam College of Pharmacy,
Vellimadukunnu, Kozhikode – 673012
Kerala
2.61
B+


Pharma Literati team provides assistance to the pharmacy institutions in various capacities. Please see the details: http://pharmaliterati.blogspot.in/2017/09/nba-naac-and-nirf-rankings-assistance.html









Thursday, 9 November 2017

National National Convergence of Pharmaceutical Sciences and Biomedical Technology - CPSBT 2018

At NIPER Ahmedabad, on 13th to 15th Feb, 2018.

AREAS FOR CALL FOR ABSTRACTS:
• Drug Design & Discovery
• Biotherapeutics
• Formulation Development of Natural & Synthetic Molecules
• Analytical QbD in Pharmaceutical Development
• Implantable Medical Devices
• Pharmacological Evaluation of Therapeutics
  
IMPORTANT DATES:
Abstract Submission Opens: November 1, 2017.
Abstract Submission Closes: December 31, 2017
Online Registration Opens: November 1, 2017.
Early bird Registration Closes: December 31, 2017.
On Spot Registration: February 13, 2018.




JOB Fair at NIPER Ahmedabad on 16th February 2018

Job Fair Registration Form
Supported by Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers Government of India ,16th February 2018
To confirm participation, send duly filled registration form/ scanned copy along with DD/RTGS/NEFT transfer of Rs.1000/-(Rs.1500/- after 31st December 2017) as registration fees in favor of National Institute of Pharmaceutical Education and Research (NIPER)- Ahmedabad payable at Gandhinagar.
The bank details for RTGS/NEFT transfer are as under:
Account Name : NIPER Ahmedabad Conference
Account No : 37271317266
IFSC : SBIN0008434

All communication should be addressed, To the Registrar, National Institute of Pharmaceutical Education and Research- Ahmedabad, Opposite Air force Station, Palaj, Gandhinagar-382355, Gujarat, jobfair_cpsbt@gmail.com

Note:
  • Participants are requested to mail/ bring sufficient copies of their CV to submit the same to different companies.
  • Should you have any query, please feel free to contact any of our organizing committee members: manju@niperahm.ac.in (+91-9099069333); govinda@niperahm.ac.in (+91-80 00247141); rakesh.tekade@niperahm.ac.in (+91-743 606 9955)

One Day Seminar on Medical Devices: Current Needs and Solutions-14th November 2017

Event: One Day Seminar on Medical Devices: Current Needs and Solutions.

Where: NIPER, Ahmedabad.

When: 14th November, 2017.

  




Large merger and acquisitions back in Indian pharma

The Rs 3600 crore acquisition of Unichem's domestic business by Torrent Pharma has brought the mojo back into India pharma's merger and acquisition scene, which was eluding large deals in the past few years.
Concerns related to the US market, which contributes major revenues for most of the leading firms, increasing regulatory concerns and price controls in the domestic market were forcing drug majors to be cautious in jumping into big deals. The struggle of leader Sun Pharma to digest its biggest acquisition, Ranbaxy Laboratories, also made drug firms cautious in executing large M&As.
Sun and Ranbaxy had merged in February 2015 in a cashless share transaction worth $3.2 billion, after an year of announcing the deal. Thereafter Indian pharma was not witnessing any large mergers.
Indian drug firms' domestic business was always an attraction for multinationals to get a footprint in India. In the largest ever transaction so far, Ajay Piramal had sold his formulation business to Abbott for nearly Rs18,000 crore in 2010. Three years later, Strides Arcolab had sold its subsidiary to Mylan for about Rs 10,000 crore. In the same year, Torrent made a Rs 2000 crore acquisition of some attractive local brands belonging to Elder Pharma.
A recent data from Grant Thornton Advisory says there were only 27 M&A deals in pharma and healthcare sector so far in 2017, valued at $719 million, compared to 54 deals valued at $4.7 billion in calendar year 2016. (After this report, Lupin acquired Symbiomix Therapeutics for $150 million and now the Rs 3600 crore Torrent-Unichem deal happened).
Two of the largest acquisitions so far this year were Piramal Enterprises' buyout of Mallinckrodt's certain drugs for $171 million and Aurobindo Pharma's acquisition of Portuguese firm Generis Farmaceutica $142.5 million.
Leading drug firms like Sun Pharma, Lupin, Zydus Cadila, Aurobindo etc. are searching for acquisitions in the specialty segment in the US market and brands or firms like Unichem in the domestic market, say investment bankers. Most of the leading firms are sitting on cash, but scrutiny is intense now due to experiences in the past. High valuations are also a roadblock in many deals, they say.
Sourcehttp://www.businesstoday.in/sectors/pharma/large-merger-and-acquisitions-back-in-indian-pharma/story/263399.html

Monday, 6 November 2017

Goa college of Pharmacy organizes 2nd Annual International Conference on Intellectual Property

2nd Annual International Conference on Intellectual Property (IP) is being organized by Goa – Center for Excellence in Intellectual Property (G-CEIP) in association with Goa College of Pharmacy on Nov. 16-17, 2017 at Goa College of Pharmacy, Panaji, Goa INDIA. The Theme of conference being Intellectual Property Matters: Prosecution to Litigation.
Experts in the field across the globe are invited as resource faculty to update delegates on the recent advances related to various aspects of IP from generation to preservation and protection. The Program is expected to attract over 100 delegates from the industry and academia from India and overseas. Experts in the field across the globe are invited as resource faculty to update delegates on the recent advances related to various aspects of IP from generation to preservation and protection. The Program is expected to attract over 100 delegates from the industry and academia from India and overseas.

Friday, 3 November 2017

22nd national convention on pharmacognosy and International conference_Jan 20-21, 2018


Presenting Pharm-Inquista (A PHARMACAD Initiative)

Learning is always fun if done in the Play Way.

A Pharma Crossword based on *GPAT / NIPER and General Awareness.* 
Helping students to Practice and Prepare for Competitive Exams. 

Solve the Crossword and send us the response at: *pharminquista@gmail.com*

*The First 3 correct responses will awarded a certificate of excellence by PHARMACAD.*

Last date of Submitting the response : *5th November 2017.*

For any queries contact: 983347166 / 9619573372



Tuesday, 31 October 2017

2nd GPAT Mock test conducted on 29th to 31st October 2017_Results

The Pharmacad mock test series for GPAT continued with it's second test. 

The winners for the 2nd test eligible for the complimentary registrations for the courses of Pharma Literati Centre of Excellence in pharma education are

1. Hardik Joshi from Bombay College of Pharmacy who scored 235/ 500 marks.

2. Sayali Tekalkar from Dr. Bhanuben Nanavati College of Pharmacy who scored 201/500 marks.

3. Komal Jain from K M Kundnani College of Pharmacy who scored 196/500 marks.


The registrations are open still and students can participate in the 3rd test scheduled in the month of November 2017.


The application form for the registration is available at,  


https://docs.google.com/forms/d/e/1FAIpQLScrC0Y_ao_SBKiSxjpLg2ws5hBIybiHi-gO2UJKO_BFF2lIWA/viewform

Sunday, 29 October 2017

Pharma Literati has a Youtube channel now

Please visit our youtube channel to get the videos of courses of Pharma Literati Centre of Excellence in Pharma Education. The videos can be viewed under the videos section. 

2 modules of CPIPR course by Mr. Mayank Gupta, Manager, Sun Pharmaceuticals have been covered currently. The videos are freely accessible to everyone. 

https://www.youtube.com/channel/UCXO0df_OUS5Xq91o3dB3erA/videos

This is another initiative which would provide us a direct connect with our readers and the activities we are involved into.......







Monday, 23 October 2017

Certificate Course in Drug Discovery and Bulk Drugs (Active Pharmaceutical Ingredient)

Pharma Literati Centre of Excellence of Pharma Education is pleased to announce its third offering in the series after CPIPR and online GPAT Test seriesFirst of its kind of a course being delivered by the industry experts "Certificate Course in Drug Discovery and Bulk Drugs  (Active Pharmaceutical Ingredient)". 

For whom?
  1. Pharmacy/ Chemistry/ Biosciences/ Life sciences/ Biotechnology/ Zoology/ Botany students in undergraduate/ post graduate / PhD/ Research fellows;
  2. Faculties form any of these streams;
  3. Industry professionals from Pharma/ Biotechnology/ Life science;
  4. Students willing to pursue higher studies in USA/Europe/ Canada/ Australia/ Russia/ Korea/ Japan/ other countries as PhD/ MBA/ MS/ Masters.
Course duration:
3 months including the live lectures.


Course fees:
Fees for the students:     Rs. 6000 + 1080 (GST) = 7080 Rs.
For others:                       Rs. 8000 + 1440 (GST) = 9440 Rs.
Send an email to pharmaliterati@gmail.com to know the mode of payment.




Registrations are open till 30th November 2017. Course starts on 1st December 2017.

Saturday, 21 October 2017

National seminar on the evolution of modern trends in pharmacy practice





1st GPAT Mock test conducted on 15th and 16th October 2017_Results

The Pharmacad mock test series for GPAT started with big bang on 15th and 16th October 2017. In a short span of just 12 days, more than 57 students appeared for the online GPAT examination. 

Students from 3 different states with more than and 6 universities participated in the test. The examination was framed in such a way soas to mimic the actual GPAT examination and was conducted online. The students appeared from the comfort of their home. Some snapshots of the examination.





Students from following institutes participated in the test:
       1.  HK College of Pharmacy, Jogeshwari.
       2.     C.U. Shah college of pharmacy, Santacruz.
3.     Bombay college of pharmacy, Kalina.
4.     Sterling institute of Pharmacy, Nerul.
5.     Saraswathi Vidya Bhavan's College of Pharmacy, Dombivali.
6.     Arya college of pharmacy, Jaipur.
7.     Department of pharmaceutical sciences, Dibrugarh University, Assam.
8.     Sudhakarrao Naik Institute of Pharmacy, Pusad Yavatmal.
9.     Oriental college of pharmacy, Sanpada.
10.  St John Institute of Pharmacy & Research. Palghar(E).
11.  Dr. Bhanuben Nanavati College of Pharmacy,  Vileparle.
12.  Shri DD Vispute college of pharmacy and research centre, Panvel.
13.  Konkan Gyanpeeth Rahul Dharkar College of Pharmacy, Karjat
14.  VES College of Pharmacy, Chembur.
15.  Channabasweshwar college of Pharmacy, Latur
16.  KM Kundnani College of Pharmacy
17.  Viva institute of Pharmacy, Virar.
18.  Ideal College of Pharmacy, Kalyan.


The winners for the 1st test eligible for the complimentary registrations for Pharma Literati Centre of Excellence in pharma education are

1. Nachiket Dandekar from Bombay College of Pharmacy who scored 237/ 500 marks.

2. Archana Rajadhyax from C U Shah College of Pharmacy who scored 232/500 marks.

3. Yogita Shinde from Shri D D Vispute College of Pharmacy who scored 220/500 marks.

Also, following students scored 200+ in the test.

1. Rama Gupta from Arya College of Pharmacy, Jaipur;
2. Pushpanjali Chavan from D D Vispute College of Pharmacy; and
3. Sayali Tekalkar from Dr. Bhanuben Nanavati College of Pharmacy.


The registrations are open still and students can participate in the 2nd test scheduled on 29th October 2017.


The application form for the registration is available at,  

https://docs.google.com/forms/d/e/1FAIpQLScrC0Y_ao_SBKiSxjpLg2ws5hBIybiHi-gO2UJKO_BFF2lIWA/viewform

Saturday, 14 October 2017

Last day to register for Online GPAT test series by Pharmacad

The Pharmacad mock test series for GPAT is starting and the 1st test would be on 15th October 2017. Give the online examination along with the students of various institutes and the toppers would get free registration for the courses by Pharma Literati.

Students from various states and institutes have already registered. 



Sunday, 8 October 2017

1st session of CPIPR conducted via "Facebook Live" on 7th Oct 2017

Team Pharma Literati conducted its first lecture for the first course of Pharma Literati Centre of Excellence in Pharma Education via Facebook Live on 7th October 2017 at 8 PM.

The lecture was delivered by Mr. Mayank Gupta, Manager, IPR, Sun Pharma, who is course faculty for the session of CPIPR. 

The readers can view the video at Pharma Literati's Facebook Page:

Also, like the page to get the facebook updates for the upcoming courses, videos and events.

The first batch of CPIPR has 43+ students and the details can be accessed at: 







Wednesday, 4 October 2017

Champion of generics_Interview of Abhijit Mukherjee, Chief Operating Officer at Dr. Reddy’s Laboratories, India By the Medicine Maker

The Medicine Maker recently published an interview of  Abhijit Mukherjee, Chief Operating Officer at Dr. Reddy’s Laboratories. We bring the same for our readers.

How did your career begin?
When I graduated from Engineering School in India during the 1980s, I didn’t have a specific career plan, but my family were keen for me to get working. At the time, the job market was dominated by a few large multinational companies – the main choices were either ICI or Unilever. I joined the latter as a management trainee in a very technical job (working with aroma chemicals and detergents), but it gave me the opportunity to work in different countries. Unilever did not encourage superficial learning, but rather the importance of going into the details. It was an important phase of my career – the early days are always a key learning experience. And working hard back then was always very much appreciated (not always the case today).

How did you transition to a business role?
I’d always had a liking for numbers – even on the shop floor I would attempt to connect any activity I was doing to a financial return. However, jumping from a technical role to a business role in the 1990s was not easy. Nevertheless, after around 13 years with Unilever, an opportunity presented itself at a large, chemical conglomerate in India, where I was involved with the business end-to-end – from manufacturing, to sales, to dealing with banks and the collection of money. I ended up heading their bulk chemical and intermediates business, before Dr. Reddy’s made me an offer in 2003 to join their management council as the Head of Custom Pharma business.

What was Dr. Reddy’s like when you joined?
At the time, the business I took charge in Dr. Reddy’s was an incubating business. Turnover was zero, but aspirations were high. I was interested in the challenge and destiny was kind. The business grew fast organically and with some quick acquisitions (in the UK and Mexico). I was also given additional charge of the API business, which I ran for a while. I then moved into the core business, eventually becoming the Chief Operating Officer around three years ago.

What are your main challenges in your current role?
The main challenges I face in my position are those which the whole generics industry faces. One major headwind is the huge number of mergers and acquisitions among pharmacy managers and retail chains in the US, which has boosted their bargaining power and created pricing pressures for generics manufacturers. The consolidation of channels has been a significant challenge for us, especially considering that over 50 percent of our business is in the US.

Another major challenge has been the increasing expectations from regulators – both in the US and elsewhere. Exports from India have rapidly increased in recent years and regulators have stepped up for valid reason to ensure high standards. I think the entire industry – ourselves included – has somewhat struggled to keep pace, but valuable lessons have been learned along the way.

Finally, macroeconomic turmoil in emerging markets has hit commodities hard. We have a fairly big presence in Russia, whose currency took a major hit in recent years, as well as Ukraine, where the situation has been even worse. But the good news is that those economies have stabilized more recently and, after such a dip, you tend to see a solid four or five years of growth ahead. I’m optimistic about emerging markets, particularly as we’ve restructured and opened some new business avenues there. We’ve set ourselves in good stead to capitalize on the current period of stability.

What makes you the most proud about your work?
Dr. Reddy’s spends in the region of 12 to 14 percent of our turnover on research and development. What really makes me proud is when those passionate efforts generate societal benefits – especially in terms of access to medicines in underserved markets. One specific example we are currently working on is the creation of institutional businesses for oncology products in emerging markets. Prices are high and access to oncology drugs is shockingly low in emerging markets – not because the prevalence of the disease is much lower than in the developing world, but because of issues around government funding. We are currently playing a significant role in delivering oncology medicines to patients in various countries across South America, Eastern Europe and Asia.

If you could change one thing about the pharma industry, what would it be?
Changing the perception of the generics industry would be at the top of my wish list. I truly believe the generics industry is creating a great deal of value in terms of accessible and affordable medicines, both in developed countries and emerging markets. But the access to generic is a constant barrier, especially in emerging markets. It’s an unspoken tragedy. By changing perceptions and the image of the industry, we might tip the balance in future, leaning in favor of generics industry – which I think would be of benefit to patients.

The generics industry seems to go through highs and lows, and I think it’s currently going through a bit of a low, but I keep telling people that now is the time to be resilient and to have confidence in your values. If we do that, I believe the next decade will be a more successful one.